
Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA edits. biotechtv.com/post/shape-the…

Shaping the future of Gene Therapy

Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA edits. biotechtv.com/post/shape-the…

How do you turn AI conversations into real progress? Next week at Benchtalk 2024, Generate’s @tharindi_h, PhD, joins @WillWeiss of @EliLillyandCo and @RonHause from @ShapeTx Inc. to discuss R&D’s toughest challenges. Don’t miss out—details here: benchtalk.benchling.com/bost…

We are pleased to welcome @DavidEpsteinRX and Todd Simpson to our board of directors. Their collective experience and expertise will be invaluable as we continue to advance our transformative science and drive growth. globenewswire.com/news-relea…

Lessons from Shape Therapeutics: How to harness AI for R&D success benchling.com/blog/lessons-f…

Very exciting news from the recent ASGCT meeting! globenewswire.com/en/news-re…

ShapeTX is once again taking over Union Square for #JPM2024! Look out for our kiosk ads throughout the area and visit ShapeTX.com to learn more about our work in engineering programmable medicines!

Heading to #JPM2024 next week? Meet with us onsite to learn more about our work creating programmable medicines with AI and RNA! Reach out via our contact form to set up a meeting: bit.ly/47mT99A

Calling all JPM Healthcare Conference attendees - join our VP of Process and Product Development, Ken Prentice as he moderates a panel on next-generation gene therapy for @GenScript's Biotech Global Forum on Jan 10 at 3:20 PM! Tickets available here: bit.ly/3S6yu4b

Our latest news update was an expansion of our partnership with @Roche. In December, @Roche added an additional target by utilizing our AI-powered RNAfix™ platform. A great way to close out 2023! Read about this and other ShapeTX news via @FierceBiotech bit.ly/3R1l4pw

We’ve enjoyed many great successes in 2023 thanks to our partners. In fall we announced our collaboration w/ Otsuka to apply our generative AI and AAVid™ capsid discovery platform w/ Otsuka’s expertise in ocular diseases to create novel treatment options bit.ly/3ZjG1je

Looking back on our proudest moments of 2023, our SVP and Head of AI Ron Hause's byline in @FastCompany is on our list! Read about how biotechs like ShapeTX are expanding the possibilities of generative AI for the next generation of drug development here: bit.ly/42XaFPC

As this year comes to a close, we're looking back on some of our proudest moments from 2023. In May, our CSO David Huss was named one of @endpts 20 under 40 in Biopharma. We're proud of David's ShapeTX accomplishments while also running 100+ mile races! bit.ly/48rrDbM

Our SVP and Head of AI Ron Hause leads a team using #generativeAI to develop programmable RNA medicines for disease treatment. What does that mean in practice? Check out Ron's Coworking feature in @etechbrew to learn more bit.ly/3uDWCmD

On the anniversary of ChatGPT's launch, @FastCompany asked asked AI leaders including our SVP and Head of AI Ron Hause how #generativeAI is changing drug development. Read their insights here: bit.ly/3RoUA2s

ICYMI - we've expanded our partnership with @Roche to add an additional target by utilizing our AI-powered RNAfix™ platform. Read the latest on this deal and our Otsuka deal from earlier this year via @FierceBiotech: bit.ly/3R1l4pw

We've expanded our work with @Roche to add a new target to our existing collaboration. For this partnership, we're conducting preclinical research to identify and deliver development candidates discovered by our AI-powered RNAfix™ platform: bit.ly/46DGwql